Goldman Sachs’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-1,397,403
| Closed | -$52.6M | – | 6827 |
|
|
2021
Q1 | $52.6M | Buy |
1,397,403
+1,171,542
| +519% | +$29.2M | 0.01% | 1135 |
|
|
2020
Q4 | $3.84M | Buy |
225,861
+68,962
| +44% | +$864K | ﹤0.01% | 3209 |
|
|
2020
Q3 | $737K | Sell |
156,899
-8,314
| -5% | -$42.2K | ﹤0.01% | 4276 |
|
|
2020
Q2 | $1.01M | Buy |
165,213
+115,767
| +234% | +$477K | ﹤0.01% | 3946 |
|
|
2020
Q1 | $112K | Sell |
49,446
-37,646
| -43% | -$160K | ﹤0.01% | 4914 |
|
|
2019
Q4 | $400K | Buy |
87,092
+1,083
| +1% | +$4.29K | ﹤0.01% | 4623 |
|
|
2019
Q3 | $333K | Sell |
86,009
-165,075
| -66% | -$906K | ﹤0.01% | 4636 |
|
|
2019
Q2 | $1.51M | Buy |
251,084
+122,360
| +95% | +$1.17M | ﹤0.01% | 3719 |
|
|
2019
Q1 | $1.73M | Sell |
128,724
-546
| -0.4% | -$6.23K | ﹤0.01% | 3732 |
|
|
2018
Q4 | $1.2M | Sell |
129,270
-69,471
| -35% | -$827K | ﹤0.01% | 3873 |
|
|
2018
Q3 | $2.77M | Buy |
198,741
+8,569
| +5% | +$127K | ﹤0.01% | 3384 |
|
|
2018
Q2 | $3.01M | Sell |
190,172
-40,003
| -17% | -$698K | ﹤0.01% | 3317 |
|
|
2018
Q1 | $3.95M | Buy |
230,175
+76,875
| +50% | +$1.5M | ﹤0.01% | 3080 |
|
|
2017
Q4 | $3.36M | Buy |
153,300
+90,810
| +145% | +$2.92M | ﹤0.01% | 3355 |
|
|
2017
Q3 | $2.56M | Sell |
62,490
-144,108
| -70% | -$4.52M | ﹤0.01% | 3761 |
|
|
2017
Q2 | $6.22M | Sell |
206,598
-10,864
| -5% | -$339K | ﹤0.01% | 2880 |
|
|
2017
Q1 | $7.86M | Buy |
217,462
+127,693
| +142% | +$5.63M | ﹤0.01% | 2569 |
|
|
2016
Q4 | $4.5M | Sell |
89,769
-564,583
| -86% | -$29.7M | ﹤0.01% | 3145 |
|
|
2016
Q3 | $34.3M | Buy |
654,352
+474,011
| +263% | +$22.6M | 0.01% | 1490 |
|
|
2016
Q2 | $7.46M | Buy |
180,341
+92,781
| +106% | +$4.04M | ﹤0.01% | 2554 |
|
|
2016
Q1 | $3.56M | Sell |
87,560
-92,278
| -51% | -$3.17M | ﹤0.01% | 2982 |
|
|
2015
Q4 | $7.46M | Buy |
179,838
+142,719
| +384% | +$4.78M | ﹤0.01% | 2491 |
|
|
2015
Q3 | $571K | Sell |
37,119
-6,580
| -15% | -$141K | ﹤0.01% | 5006 |
|
|
2015
Q2 | $1.08M | Buy |
43,699
+23,630
| +118% | +$526K | ﹤0.01% | 4469 |
|
|
2015
Q1 | $459K | Buy |
20,069
+9,549
| +91% | +$241K | ﹤0.01% | 5220 |
|
|
2014
Q4 | $284K | Sell |
10,520
-463,852
| -98% | -$7.98M | ﹤0.01% | 5846 |
|
|
2014
Q3 | $5.56M | Sell |
474,372
-32,417
| -6% | -$409K | ﹤0.01% | 2911 |
|
|
2014
Q2 | $7.88M | Buy |
506,789
+3,497
| +0.7% | +$50.2K | ﹤0.01% | 2588 |
|
|
2014
Q1 | $9.89M | Buy |
503,292
+24,326
| +5% | +$413K | ﹤0.01% | 2375 |
|
|
2013
Q4 | $8.04M | Buy |
+478,966
| New | +$5.95M | ﹤0.01% | 2576 |
|
Goldman Sachs's FPRX Position: Q2 2021 in Review
Goldman Sachs sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 1,397,403 shares — an estimated $52.6M sold.
Goldman Sachs first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $52.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Goldman Sachs reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Goldman Sachs sold 1,397,403 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $52.6M.
- Goldman Sachs first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Goldman Sachs's Five Prime Therapeutics, Inc. position peaked at $52.6M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.